Related Experiment Videos
[Genetic tumour diagnostics and personalised medicine from a systems perspective]
1AOK-Bundesverband, Berlin, Deutschland.
Summary
High-quality studies are crucial for personalized medicine, especially with new genomic sequencing in oncology. Ensuring robust evidence requires interdisciplinary collaboration and integrated research funding models for patient benefit.
Area of Science:
- Biomedical research
- Oncology
- Genomic medicine
Context:
- Personalized medicine relies on evaluating biomarker tests and treatments.
- Genome sequencing in oncology introduces numerous new treatment concepts.
- Current evidence for these new concepts is often of low quality.
Purpose:
- To emphasize the necessity and feasibility of high-quality studies in personalized medicine.
- To address the expected influx of low-quality evidence from genomic sequencing in oncology.
- To outline requirements for generating reliable evidence in this field.
Summary:
- High-quality studies are essential for assessing patient-relevant outcomes in personalized medicine.
- The integration of genome sequencing in oncology necessitates rigorous evaluation of novel treatments.
- Key requirements include high quality standards, interdisciplinary collaboration, and integrated funding for care and research.
Impact:
- Facilitates evidence-based adoption of new genomic cancer therapies.
- Improves patient outcomes through reliable treatment evaluations.
- Guides healthcare policy for integrating innovative diagnostics and therapeutics.